1
|
Botanas CJ, de la Peña JB, Dela Pena IJ, Tampus R, Kim HJ, Yoon SS, Seo JW, Jeong EJ, Cheong JH. Evaluation of the abuse potential of AM281, a new synthetic cannabinoid CB1 receptor antagonist. Eur J Pharmacol 2015; 766:135-41. [PMID: 26450088 DOI: 10.1016/j.ejphar.2015.10.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2015] [Revised: 08/29/2015] [Accepted: 10/02/2015] [Indexed: 11/30/2022]
Abstract
AM281 (1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-4-morpholinyl-1H-pyrazole-3-carboxamide) is a new synthetic cannabinoid CB1 receptor antagonist. Similar to other cannabinoid antagonists, AM281 has been suggested to have therapeutic indications. However, recent reports have suggested that cannabinoid CB1 receptor antagonists may share similar behavioral effects with other drugs of abuse such as cocaine and amphetamine. These reports cast doubts on the safety profile of AM281. Thus, in the present study we evaluated the abuse potential (rewarding and reinforcing effects) of AM281 through two of the most widely used animal models for assessing the abuse potential of drugs: the conditioned place preference (CPP) and self-administration (SA) tests. Experiments were performed in Sprague-Dawley rats in various dosages [CPP (0.1, 0.5 or 2.5mg/kg), SA (0.005, 0.025 or 0.1mg/kg/infusion)]. We also delved into the consequences of repeated drug exposure on the subsequent response to the drug. Thus, parallel experiments were carried out in rats pretreated with AM281 for 7 or 14 days. Our findings indicated that AM281, at any dose, did not induce CPP and SA in drug-naïve rats. Interestingly, significant CPP (0.5mg/kg of AM281), but not SA, was observed in 14 days pretreated rats. These observations suggest that AM281 per se has no or minimal rewarding and reinforcing properties, but alterations in neuronal functions and behavior due to repeated AM281 exposure may contribute in part to the abuse potential of this drug. In view of this finding, we advocate the careful use, monitoring, and dispensation of AM281.
Collapse
Affiliation(s)
- Chrislean Jun Botanas
- Uimyung Research Institute for Neuroscience, School of Pharmacy, Sahmyook University, 26-21 Kongreung-2-dong, Hwarangro-815 Nowon-gu, Seoul 139-742, Republic of Korea
| | - June Bryan de la Peña
- Uimyung Research Institute for Neuroscience, School of Pharmacy, Sahmyook University, 26-21 Kongreung-2-dong, Hwarangro-815 Nowon-gu, Seoul 139-742, Republic of Korea
| | - Irene Joy Dela Pena
- Uimyung Research Institute for Neuroscience, School of Pharmacy, Sahmyook University, 26-21 Kongreung-2-dong, Hwarangro-815 Nowon-gu, Seoul 139-742, Republic of Korea
| | - Reinholdgher Tampus
- Uimyung Research Institute for Neuroscience, School of Pharmacy, Sahmyook University, 26-21 Kongreung-2-dong, Hwarangro-815 Nowon-gu, Seoul 139-742, Republic of Korea
| | - Hee Jin Kim
- Uimyung Research Institute for Neuroscience, School of Pharmacy, Sahmyook University, 26-21 Kongreung-2-dong, Hwarangro-815 Nowon-gu, Seoul 139-742, Republic of Korea
| | - Seong Shoon Yoon
- Center for Safety Pharmacology, Korea Institute of Toxicology, Daejeon 305-343, Republic of Korea
| | - Joung-Wook Seo
- Center for Safety Pharmacology, Korea Institute of Toxicology, Daejeon 305-343, Republic of Korea
| | - Eun Ju Jeong
- Center for Safety Pharmacology, Korea Institute of Toxicology, Daejeon 305-343, Republic of Korea
| | - Jae Hoon Cheong
- Uimyung Research Institute for Neuroscience, School of Pharmacy, Sahmyook University, 26-21 Kongreung-2-dong, Hwarangro-815 Nowon-gu, Seoul 139-742, Republic of Korea.
| |
Collapse
|
3
|
Spivey AC, Tseng CC, Jones TC, Kohler AD, Ellames GJ. A method for parallel solid-phase synthesis of iodinated analogues of the CB1 receptor inverse agonist rimonabant. Org Lett 2009; 11:4760-3. [PMID: 19778010 DOI: 10.1021/ol902038y] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
A method for the parallel solid-phase synthesis (SPS) of iodinated analogues of Sanofi-Aventis' type 1 cannabinoid (CB1) receptor inverse agonist rimonabant (acomplia) has been developed. The method allows the synthesis of a range of C3 amide/hydrazide derivatives from a resin-bound C3 ester precursor. The C-Ge linkage to the Hypogel-200 resin is stable to the diversification conditions but allows ipso-iododegermylative cleavage using NaI/NCS even for the products containing the oxidatively labile hydrazide moiety.
Collapse
Affiliation(s)
- Alan C Spivey
- Department of Chemistry, Imperial College, London SW7 2AY, UK.
| | | | | | | | | |
Collapse
|
5
|
Nojiri Y, Ishiwata K, Qinggeletu, Tobiishi S, Sasada T, Yamamoto F, Mukai T, Maeda M. Radiosynthesis and Biodistribution in Mice of a 18F-Labeled Analog of O-1302 for Use in Cerebral CB1 Cannabinoid Receptor Imaging. Biol Pharm Bull 2008; 31:1274-8. [PMID: 18520068 DOI: 10.1248/bpb.31.1274] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
- Yumiko Nojiri
- Graduate School of Pharmaceutical Sciences, Kyushu University
| | - Kiichi Ishiwata
- Positron Medical Center, Tokyo Metropolitan Institute of Gerontology
| | - Qinggeletu
- Positron Medical Center, Tokyo Metropolitan Institute of Gerontology
| | | | - Toru Sasada
- Positron Medical Center, Tokyo Metropolitan Institute of Gerontology
| | | | - Takahiro Mukai
- Graduate School of Pharmaceutical Sciences, Kyushu University
| | - Minoru Maeda
- Graduate School of Pharmaceutical Sciences, Kyushu University
| |
Collapse
|
6
|
Tobiishi S, Sasada T, Nojiri Y, Yamamoto F, Mukai T, Ishiwata K, Maeda M. Methoxy- and Fluorine-Substituted Analogs of O-1302: Synthesis and in Vitro Binding Affinity for the CB1 Cannabinoid Receptor. Chem Pharm Bull (Tokyo) 2007; 55:1213-7. [PMID: 17666847 DOI: 10.1248/cpb.55.1213] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Methoxy and fluorine analogs substituted on the terminal carbon of the pentyl chain of N-(piperidinyl)-1-(2,4-dichlorophenyl)-4-methyl-5-(4-pentylphenyl)-1H-pyrazole-3-carboxamide (O-1302) were synthesized in a multi-step process from 5-phenyl-1-pentanol, which was based on the 1,5-diarylpyrazole core template of N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716) through condensation of the respective amine with pyrazole carboxylic acid, in order to develop tracers for medical imaging. Their potency for inhibiting the binding of the CB1 antagonist [(3)H]SR141716 was evaluated with the aim of developing positron emission tomography (PET) ligands for the cerebral cannabinoid CB1 receptor. These analogs bearing a piperidinyl carboxamide at the C(3) of the pyrazole ring exhibited affinities comparable to those of the CB1 reference antagonist SR141716, which warrants further investigation using the radiolabeled form for biological imaging studies. A morpholine ring substituted at the C(3) of the pyrazole ring resulted in a reduction of the CB1 affinity.
Collapse
Affiliation(s)
- Shintaro Tobiishi
- Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan
| | | | | | | | | | | | | |
Collapse
|